CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study.

[1]  E. Kubista,et al.  Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer. , 1989, European journal of cancer & clinical oncology.

[2]  D. Kiang,et al.  Tumor marker kinetics in the monitoring of breast cancer , 1990, Cancer.

[3]  E. Cooper,et al.  Use of mucin like cancer associated antigen (MCA) in the management of breast cancer. , 1991, British Journal of Cancer.

[4]  R. de Wit,et al.  A comparison of CA-549 with CA 15-3 and MCA in patients with metastatic breast cancer. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. Bruning,et al.  MAM-6 antigen, a new serum marker for breast cancer monitoring. , 1986, Cancer research.

[6]  C. Loprinzi,et al.  Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Silverberg,et al.  Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma. , 1993, Clinical chemistry.

[8]  D. Ettinger,et al.  A new biomarker in monitoring breast cancer: CA 549. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Dombernowsky,et al.  Carbohydrate antigen 549 in metastatic breast cancer during cytostatic treatment and follow-up. , 1992, European journal of cancer.

[10]  A. Howell,et al.  Assessment of four monoclonal antibodies as serum markers in breast cancer. , 1990, European journal of cancer.

[11]  J. Schlom,et al.  Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. , 1984, Hybridoma.

[12]  R. Gelman,et al.  Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. , 1988, Cancer research.

[13]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[14]  Á. Ruibal,et al.  Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease , 1989, Cancer.

[15]  Smith Re.  Biochemical detection of recurrent breast cancer. , 1988 .

[16]  D. Hayes,et al.  Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. , 1985, The Journal of clinical investigation.

[17]  J. Ragaz,et al.  Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma. , 1991, Cancer research.

[18]  J. Koda,et al.  Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker. , 1987, Cancer research.

[19]  J. Müller-Brand,et al.  Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15-3. , 1991, European journal of cancer.

[20]  B. Takács,et al.  Mucin-like carcinoma-associated antigen defined by three monoclonal antibodies against different epitopes. , 1988, Cancer research.

[21]  D. Ettinger,et al.  Monitoring breast cancer with CA 549. , 1988, Clinical chemistry.

[22]  M. Price.  High molecular weight epithelial mucins as markers in breast cancer. , 1988, European journal of cancer & clinical oncology.

[23]  R. Blamey,et al.  Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15.3: fact or fiction? , 1991, Disease markers.

[24]  F. Pannuti,et al.  CA 15.3 and CEA Plasma Level Monitoring in Patients with Breast Cancer , 1988, The International journal of biological markers.

[25]  CA-549 Serum Levels in Breast Cancer Monitoring , 1992, The International journal of biological markers.

[26]  Y. Collan,et al.  Use of tumor markers CA 15-3, MCA and CEA in breast cancer diagnostics , 1989 .

[27]  M. Gion.  Serum markers in breast cancer management , 1992 .